A Randomized Phase II Trial Using Dendritic Cells Transduced With an Adenoviral Vector Containing the p53 Gene to Immunize Patients With Extensive Stage Small Cell Lung Cancer in Combination With Chemotherapy With or Without All Trans Retinoic Acid
- To determine if the combination of autologous dendritic cell-adenovirus p53 vaccine and
subsequent chemotherapy (with paclitaxel after progression) will result in a
substantial improvement in the clinical response in patients with extensive stage small
cell lung cancer.
- To determine if the addition of tretinoin to autologous dendritic cell-adenovirus p53
vaccine improves the objective tumor response rate achieved with the vaccine, by
comparing the response to vaccine treatment of patients in arm II to those in arm III.
- To evaluate the survival of all patients enrolled on an intent-to-treat basis, with a
comparison made between the three arms.
- To determine the frequency of antigen-specific T-cell responses that are induced in the
patients over time, with comparisons made between treatment arms II and III.
- To determine the efficacy of tretinoin in reducing the number of immature myeloid cells
in patients, by comparing the numbers observed in the peripheral blood of patients in
arm II as compared to arm III.
- Standard first-line chemotherapy: Patients receive standard first-line chemotherapy
comprising carboplatin IV over 1 hour on day 1 and etoposide IV over 1 hour on days
1-3. Treatment repeats every 21 days for up to 4 courses. Patients undergo restaging
after completion of first-line chemotherapy. Patients with progressive disease do not
receive any protocol treatment and are changed to second-line therapy.
- Adjuvant therapy: Patients with stable disease or better are then randomized to 1 of 3
arms of adjuvant therapy approximately 3 weeks after completion of first-line
- Arm I (Observation only [standard care]): Patients undergo observation with serial
- Arm II (Vaccine): Patients receive autologous dendritic cell-adenovirus p53
vaccine intradermally every 2 weeks for 3 doses. Patients with no sign of disease
progression will undergo another leukapheresis and receive autologous dendritic
cell-adenovirus p53 vaccine intradermally every 4 weeks for 3 doses.
- Arm III (Vaccine and tretinoin): Patients receive autologous dendritic
cell-adenovirus p53 vaccine for up to 6 doses as in arm II. They also receive oral
tretinoin for 3 days before receiving each dose of the vaccine.
Patients who develops evidence of disease progression at any point proceed to second-line
chemotherapy with paclitaxel once every 21 days in the absence of disease progression or
All patients undergo blood collection periodically for immunogenic analysis. After
completion of study treatment, patients are followed for at least 30 days.
Allocation: Randomized, Primary Purpose: Treatment
Complete response rate
Alberto Chiappori, MD
H. Lee Moffitt Cancer Center and Research Institute
|H. Lee Moffitt Cancer Center and Research Institute at University of South Florida||Tampa, Florida 33612|